e-learning
resources
Barcelona 2013
Monday, 09.09.2013
Novel drugs for the treatment of asthma and COPD
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
An antedrug of the CXCL12 neutraligand blocks experimental allergic asthma without systemic effect in the mouse
F. Daubeuf, M. Hachet-Haas, P. Gizzi, V. Gasparik, D. Bonnet, V. Utard, M. Hibert, N. Frossard, J. L. Galzi (Illkirch, France)
Source:
Annual Congress 2013 –Novel drugs for the treatment of asthma and COPD
Session:
Novel drugs for the treatment of asthma and COPD
Session type:
Oral Presentation
Number:
1760
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
F. Daubeuf, M. Hachet-Haas, P. Gizzi, V. Gasparik, D. Bonnet, V. Utard, M. Hibert, N. Frossard, J. L. Galzi (Illkirch, France). An antedrug of the CXCL12 neutraligand blocks experimental allergic asthma without systemic effect in the mouse. Eur Respir J 2013; 42: Suppl. 57, 1760
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Respiratory sequelae of preterm birth across the life span
Time to breathe: Challenges in the successful management of asthma during conception, pregnancy and delivery
Related content which might interest you:
Activation of the β-catenin pathway by Wnt-1 treatment suppress inflammation in the mouse model of allergic airway disease
Source: International Congress 2015 – Advances in asthma and allergy in animal models
Year: 2015
Effect of roflumilast on airway remodeling in a murine model of chronic asthma
Source: International Congress 2015 – New models for treating airway diseases
Year: 2015
The effect of the novel SHIP1 activator AQX-1125 on allergen-induced responses in mild to moderate asthma
Source: Annual Congress 2013 –New drugs in respiratory medicine
Year: 2013
IL-37 requires IL18Rα and SIGIRR to diminish experimental allergic airway inflammation in mice
Source: International Congress 2015 – Animal studies of asthma and other inflammatory conditions
Year: 2015
GARP reduces inflammation in a humanized mouse model of allergic airway disease
Source: International Congress 2015 – Advances in asthma and allergy in animal models
Year: 2015
Combining an epithelial repair factor and anti-fibrotic with a corticosteroid offers optimal treatment for the pathogenesis of allergic airways disease
Source: International Congress 2016 – Novel mechanisms and treatment modalities in asthma
Year: 2016
The effects of clinically relevant reference agents in a mouse model of severe asthma
Source: International Congress 2015 – Advances in the future treatment of severe asthma
Year: 2015
Neutraligands of CXCL12: Anti-inflammatory activity in an allergic model of asthma
Source: Annual Congress 2011 - Models of disease and drug actions
Year: 2011
A novel inhaled PI3Kδ inhibitor, LAS194223 reduces allergen-induced airway inflammation in rat
Source: International Congress 2014 – New drugs for asthma, COPD and pulmonary fibrosis
Year: 2014
Resveratrol upregalates PTEN and inhibits MUC5AC expression in ovalbumin (OVA)-induced asthma model mice
Source: International Congress 2016 – Preclinical pharmacology: drug targets and mechanisms of action
Year: 2016
Dose-dependent differential effects of thrombin in allergic bronchial asthma
Source: Annual Congress 2013 –Murine models of lung immunology
Year: 2013
IL-13-induced cytokine release and hyperresponsiveness in precision cut lung slices of different species – Characterization of a model potentially suitable for translational research of asthma cellular events
Source: Annual Congress 2013 –Origins and diagnosis of asthma
Year: 2013
Bronchodilator effect of a novel inhaled dual PDE3/4 inhibitor, RPL554, in mild allergic asthma & rhinitis
Source: Annual Congress 2013 –Asthma and COPD drugs: efficacy, safety and pharmacoeconomics
Year: 2013
Treatment with Syk inhibitors after establishment of disease phenotype in a chronic HDM model of allergic airways inflammation abolishes AHR and attenuates inflammatory mediator expression
Source: International Congress 2015 – New targets and modalities for the treatment of asthma and COPD
Year: 2015
Lung specific induction of Wnt-1 has a prophylactic and therapeutic effect on the development of an allergic airway disease
Source: Annual Congress 2013 –Murine models of lung immunology
Year: 2013
The effect of anti-IL-33 antibody and soluble ST2 in a murine model of allergic asthma
Source: Annual Congress 2013 –Murine models of lung immunology
Year: 2013
IL33 and TSLP involvements in influenza-induced exacerbation in a murine model of chronic asthma
Source: International Congress 2015 – Advances in asthma and allergy in animal models
Year: 2015
The anti-inflammatory effects of PF03715455 and roflumilast on both cellular and tissue inflammation in a mouse model of COPD
Source: Annual Congress 2013 –New drugs in respiratory medicine
Year: 2013
IL-25 induces airways angiogenesis and expression of multiple angiogenic factors in a murine asthma model
Source: International Congress 2015 – Asthma and lung immunology
Year: 2015
Preventative administration of IL-27 improves airway inflammation of ovalbumin –induced asthma mice model via both STAT1 and GADD45γ/p38MAPK pathways
Source: International Congress 2016 – Pharmacological intervention in humans and murine models of asthma
Year: 2016
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept